Overall 7.3 x 10.2 x 3.1cm (2 7/8 x 4 x 1 1/4in) ...

NEW YORK, Nov 19 (Reuters) - A federal judge on Tuesday rejected Pfizer's (PFE.N), opens new tab bid to recoup about $75.2 million left over from a U.S. Securities and Exchange Commission insider ...

This would mark the year of rebound for Pfizer, after it saw its sales plunge 42% y-o-y to $58.5 billion in 2023, versus $100.3 billion in 2022. The rise in 2021 and 2022 sales for Pfizer was ...

Paxlovid sales surge to $2.7 billion, beating expectations Pfizer raises annual revenue forecast for COVID products to $10.5 billion Pfizer management faces pressure from activist hedge fund ...

Pfizer (NYSE:PFE) shares perked up in the premarket on Tuesday as the New York-based pharma giant beat Street forecasts with its Q3 financials and increased its full-year outlook thanks to ...

Pfizer (PFE) CEO Albert Bourla is bullish about the company's near-term outlook after a flubbed attack campaign from activist investor Starboard Value earlier this month. "We have launched an ...

Pfizer's COVID-19 products continue to generate significant cash flow that helps bolster the company's dividend. The big drugmaker has opportunities to monetize assets to raise additional cash ...

Pfizer’s respiratory syncytial virus (RSV) pipeline appears to have run dry of candidates following the cessation of work on both an oral medicine and an RSV-flu combo vaccine in quick succession.

Wall Street analysts reasoned out why Pfizer (NYSE:PFE) shares could be under pressure on Tuesday even as the New York-based pharma giant delivered better-than-expected financials for Q3 2024 and ...

Paxlovid on its own drove much of Pfizer’s total sales (PDF) haul of $17.7 billion, up 32% year-over-year. Taking out COVID revenues, the company pulled $13.6 billion in sales in a 14% jump ...

(Reuters) -Pfizer CEO Albert Bourla, under pressure from activist hedge fund Starboard Value, made his case to Wall Street on Tuesday that the drugmaker's turnaround is succeeding after it ...

Pfizer Inc.’s stock was unable to hold its early gains Tuesday and fell 2.4% after the company blew past estimates for the third quarter and raised its full-year guidance. The New York-based ...